The existing clinical biomarkers for prostate cancer (PCa) are not ideal, since they cannot specifically differentiate between those patients who should be treated immediately and those who should avoid overtreatment. Current screening techniques lack specificity, and a decisive diagnosis of PCa is based on prostate biopsy. Although PCa screening is widely utilized nowadays, two-thirds of the biopsies performed are still unnecessary. Thus, the discovery of noninvasive PCa biomarkers remains an urgent unmet medical need. Once metastasized, there is still no curative therapy. A better understanding of sustained androgen receptor signaling in castration resistant prostate cancer (CRPC) has now led to the development of more effective therapies. We need a better understanding of the molecular and cellular aspects of prostate carcinogenesis and progression. Identification of cancer initiating cells and therapies against these population(s) is a promising way forward to fight this disease.

We invite investigators to contribute original research articles as well as review articles that bridge the laboratory and the clinic. We are particularly interested in articles describing molecular and cellular pathology of prostate cancer, preclinical animal models, molecular alterations or biomarkers that predict response or resistance to treatment, new insights into cancer stem cells, and current concepts in the prevention, treatment, and imaging of prostate cancer. Potential topics include, but are not limited to:

• Preclinical animal models
• Cancer stem cell biology
• Diagnostic, prognostic, and predictive biomarkers
• Noncoding RNA
• Exosomes
• Metastasis
• Imaging
• Treatment/drug development

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/urology/pcr/ according to the following timetable: